Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: A cost consequences analysis of data from the FARO study

Daniela Paola Roggeri, Sandro Mazzaferro, Diego Brancaccio, Giuseppe Cannella, Piergiorgio Messa, Marina Di Luca, Massimo Morosetti, Anna Maria Costanzo, Umberto Di Luzio Paparatti, Dante Cornago, Mario Cozzolino

Research output: Contribution to journalArticlepeer-review

Abstract

Background and objectives: Secondary hyperparathyroidism (SHPT) is a frequent complication of CKD with incidence, prevalence, and costs increasing worldwide. The objective of this analysis was to estimate therapy cost of SHPT in a subpopulation of the FARO study. Materials and methods: In the FARO study, an observational survey aimed to evaluate patterns of treatment in patients with SHPT who had undergone hemodialysis, pharmacological treatments and biochemical parameters evolution data were collected in four surveys. Patients maintaining the same treatment in all sessions were grouped by type of treatment and evaluated for costs from the Italian National Health Service perspective. Results: Four cohorts were identified: patients treated with oral (PO) calcitriol (n=182), intravenous (IV) calcitriol (n=34), IV paricalcitol (n=62), and IV paricalcitol+cinacalcet therapy (n=20); the cinacalcet monotherapy group was not analysed due to low number of patients (n=9). Parathyroid hormone (PTH) level at baseline and effectiveness of treatments in suppressing PTH level were assessed to test comparability among cohorts: calcitriol PO patients were significantly less severe than others (PTH level at baseline lower than 300 pg/ml; p

Original languageEnglish
Pages (from-to)1110-1117
Number of pages8
JournalJournal of Medical Economics
Volume15
Issue number6
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Cost consequences analysis
  • Haemodialysis
  • Secondary Hyperparathyroidism
  • Therapy cost

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: A cost consequences analysis of data from the FARO study'. Together they form a unique fingerprint.

Cite this